AU2420101A - Method and composition for the treatment of pain - Google Patents

Method and composition for the treatment of pain

Info

Publication number
AU2420101A
AU2420101A AU24201/01A AU2420101A AU2420101A AU 2420101 A AU2420101 A AU 2420101A AU 24201/01 A AU24201/01 A AU 24201/01A AU 2420101 A AU2420101 A AU 2420101A AU 2420101 A AU2420101 A AU 2420101A
Authority
AU
Australia
Prior art keywords
pain
treatment
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU24201/01A
Inventor
Thomas Michael Bare
Dean Gordon Brown
Carey Lynn Horchler
Frances Marie Mclaren
Megan Murphy
Rebecca Ann Urbanek
Wenhua Xiao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of AU2420101A publication Critical patent/AU2420101A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/503—Pyridazines; Hydrogenated pyridazines spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
AU24201/01A 1999-12-23 2000-12-19 Method and composition for the treatment of pain Abandoned AU2420101A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US17190699P 1999-12-23 1999-12-23
US60171906 1999-12-23
US23678500P 2000-09-29 2000-09-29
US60236785 2000-09-29
PCT/SE2000/002608 WO2001047524A1 (en) 1999-12-23 2000-12-19 Method and composition for the treatment of pain

Publications (1)

Publication Number Publication Date
AU2420101A true AU2420101A (en) 2001-07-09

Family

ID=26867557

Family Applications (1)

Application Number Title Priority Date Filing Date
AU24201/01A Abandoned AU2420101A (en) 1999-12-23 2000-12-19 Method and composition for the treatment of pain

Country Status (4)

Country Link
EP (1) EP1244453A1 (en)
JP (1) JP2003518500A (en)
AU (1) AU2420101A (en)
WO (1) WO2001047524A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002026738A1 (en) * 2000-09-29 2002-04-04 Astrazeneca Ab 1,2,5,10-TETRAHYDROPYRIDAZINO[4,5-b]QUINOLINE-1,10-DIONES AND THEIR USE FOR THE TREATMENT OF PAIN
EP1325004A1 (en) 2000-09-29 2003-07-09 AstraZeneca AB 1,2,5,10-tetrahydropyridazino[4,5-b]quinoline-1,10-diones and their use for the treatment of pain
AU2001292499A1 (en) * 2000-09-29 2002-04-08 Astrazeneca Ab 7-chloro-4-hydroxy-2-(2-pyridylethyl)-1,2,5,10- tetrahydropyridazino(4,5-b)quinoline-1,10-dione and the use thereof for the treatment of pain
US20050070544A1 (en) * 2000-09-29 2005-03-31 Astrazeneca Ab 1,2,5,10-tetrahydropyridazino{4,5-b}quinoline-1,10-diones and their use for the treatment of pain
SE0403172D0 (en) * 2004-12-23 2004-12-23 Astrazeneca Ab Manufacturing process
CN104761466A (en) * 2007-05-29 2015-07-08 英特拉克森公司 Chiral diacylhydrazine ligands for modulating expression of exogenous genes via ecdysone receptor complex

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL111266A (en) * 1993-10-22 2002-03-10 Zeneca Ltd 2-HETEROARYL OR 2-ARYLPYRIDAZINO [4,5-b] QUINOLINE - 1, 10 - DIONES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
GB9507318D0 (en) * 1995-04-07 1995-05-31 Zeneca Ltd Alpha substituted pyridazino quinoline compounds

Also Published As

Publication number Publication date
JP2003518500A (en) 2003-06-10
WO2001047524A1 (en) 2001-07-05
EP1244453A1 (en) 2002-10-02

Similar Documents

Publication Publication Date Title
HK1048949A1 (en) Method and composition for the treatment of scars
AU6872498A (en) Method and composition for skin treatment
AU5788300A (en) Medical treatment method and kit
AU4205100A (en) Methods and compositions for the treatment of pancreatitis
AU2003200731A1 (en) Compositions and methods for the treatment of tumor
AU2003200740A1 (en) Compositions and methods for the treatment of tumor
AU2003200722A1 (en) Compositions and methods for the treatment of tumor
AU2212299A (en) Compositions and methods for the treatment of tumor
AU7748000A (en) Method and composition for the treatment of dermatologic diseases
AU2495200A (en) Compositions and methods for the treatment of tumor
AU3784999A (en) Methods for treatment of pain
AU6056500A (en) Process and composition for temporarily suppressing pain
AU3896900A (en) Treatment of pain
AU2420101A (en) Method and composition for the treatment of pain
AU2566201A (en) Compounds and methods for the treatment of pain
IL150202A0 (en) Method and composition for the treatment of pain
AU5169200A (en) Methods and compositions for treating breakthrough pain
AU4598400A (en) Method of treatment
AU2683500A (en) Compositions for the treatment of pain
IL150208A0 (en) Compound and method for the treatment of pain
AU2420201A (en) Compounds and methods for the treatment of pain
AU2382601A (en) Novel method of treatment
AU2224800A (en) Compositions and methods for the treatment of tumor
AU1621501A (en) Methods and compositions for treatment of disease
AU2003200032A1 (en) Method of treatment and pharmaceutical composition

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase